Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) COO Sells 5,209 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.51, for a total transaction of $39,119.59. Following the completion of the transaction, the chief operating officer now directly owns 91,253 shares in the company, valued at approximately $685,310.03. This represents a 5.40 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Daniel Lesueur also recently made the following trade(s):

• On Tuesday, November 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $7.70, for a total value of $40,109.30.

Health Catalyst Stock Down 6.4 %

Shares of HCAT traded down $0.47 during midday trading on Friday, hitting $6.89. The company had a trading volume of 477,428 shares, compared to its average volume of 533,036. The stock has a market cap of $419.24 million, a price-to-earnings ratio of -5.10 and a beta of 1.36. The company’s 50 day moving average price is $7.81 and its 200 day moving average price is $7.52. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a 52 week low of $5.42 and a 52 week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same period in the prior year, the firm earned ($0.22) earnings per share. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, equities research analysts predict that Health Catalyst, Inc. will post -0.33 EPS for the current year.

Analysts Set New Price Targets

HCAT has been the subject of several analyst reports. Evercore ISI upped their target price on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Citigroup decreased their price target on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday. Royal Bank of Canada lifted their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research note on Friday, October 4th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $11.45.

Hedge Funds Weigh In On Health Catalyst

Several large investors have recently added to or reduced their stakes in HCAT. Quest Partners LLC bought a new stake in Health Catalyst during the third quarter valued at $34,000. Quarry LP boosted its holdings in shares of Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after buying an additional 2,610 shares during the period. nVerses Capital LLC bought a new stake in shares of Health Catalyst during the 3rd quarter valued at about $59,000. Mackenzie Financial Corp acquired a new stake in Health Catalyst during the second quarter worth about $70,000. Finally, Quadrature Capital Ltd acquired a new position in Health Catalyst in the third quarter valued at approximately $84,000. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.